Akebia Therapeutics shares are trading higher after HC Wainwright & Co. maintained a Buy rating on the stock and raised its price target from $6 to $7.5.
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics shares are trading higher after HC Wainwright & Co. maintained a Buy rating on the stock and raised its price target from $6 to $7.5.
August 12, 2024 | 2:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintained a Buy rating on Akebia Therapeutics and raised its price target from $6 to $7.5, leading to a rise in the stock price.
The positive analyst rating and increased price target from a reputable firm like HC Wainwright & Co. are likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100